MAPT and amyloidosis: We identified 166 (57%) participants without brain amyloidosis or tau pathology (A-T-, 60% female, mean age 60 years), 26 (9%) participants with amyloid aggregation without detectable tau accumulation by PET (A+T-, 54% female, mean age 72 years), 39 (14%) participants with brain amyloidosis and tau accumulation in Braak stages I–IV (A+TBraak I–IV, 67% female, mean age 72 years), and 58 (20%) participants with Aβ accumulation in the brain and tau accumulation in Braak stages V or VI (A+TBraak V+, 57% female, mean age 69 years).